This month we've been watching how different companies are managing their pipelines, and keeping Eyes On other hot news topics.

According to an annual PwC study released in December, the amount of M&A activity in the pharmaceutical and life sciences sectors in 2024...

This week, we had eyes on data readouts, launch metrics, M&A, and more. Catch up with the news from Roche, AstraZeneca, Lundbeck, and AbbVie

Last month, we had Eyes On some of the latest approvals, M&A and litigation. Read more about AbbVie, Genentech, Lundbeck, and GSK ...

This month, we've had Eyes on investment trends, strategic restructuring, and FDA decisions. Fall seems to be gearing up, and we can't wait

We've had our Eyes On some of the latest Pharmaceutical news including approvals, partnering, mergers, research programs, and

News & Views - sharing some oncology, AZD, M&A tidbits that caught our eye.

his week we've been looking at the competition heating up due to a combination of M&A, biosimilar entrants, and new clinical data ...

We've had Eyes On recent news further clarifying company restructures. In the midst of refining pipelines, and cutting corporate spending ..

We've been keeping Eyes On Deals & Raises in the BioPharma sector for the first quarter of 2024. Things seem to be heating-up ...

We've been trying to keep up with current events - here's some of what we've hay Eyes On this week.

Some of the highlights include AI medical advancements, strategic industry movements, regulatory updates, & challenges within the pharma ...

This week we've had Eyes how BioPharma are bolstering their Portfolios for long-term success. From licensing assets ...

We’ve had Eyes On – Some of the Post Holiday /Pre-Earnings News Snippets As the companies and the markets gear up for Results, tucked in...